Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + Lapatinib in ErbB2+ Inflammatory Breast Cancer
NCT00558103Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2007
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 2 trial of pazopanib in inflammatory breast cancer (IBC), sponsored by GSK. Started Dec 2007; status: completed.
02
Drugs
pazopanib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT00558103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558103.